USE OF ELTROMBOPAG IN ROUTINE CLINICAL PRACTICE


OBJECTIVES
1. To evaluate the use of eltrombopag in routine clinical practice and its compliance with the Summaries of product characteristics (SmPC).
2. To measure the efficacy according to platelet count response and the need for other concomitant treatments.

MATERIALS AND METHODS
Observational, retrospective and descriptive study of adult patients who received treatment with eltrombopag from 06/2020 to 10/2021. Efficacy was established according to platelet counts three and six months after initiation of treatment, aiming for values between 50.000-150.000 platelets/µL (pl/µL).

The following variables were collected from the electronic medical record:
- Demographic data
- Therapeutic indication
- Initial dose
- Platelet count
- Concomitant treatments related to hemostasis

RESULTS
N= 35 (54% women) Median age: 68 years (26-95)

ON-LABEL USE

OFF-LABEL USE

INITIAL DOSE

*The initial dosing indicated by the SmPC is 50mg per day

PLATELET COUNT

**Concomitant treatments related to hemostasis**
- Received previous cycles of corticosteroids (19)* Some patients received subsequent treatment as well
- Eltrombopag + Prednisone (6)
- Eltrombopag + Immunoglobulins (2)
- Eltrombopag + Cyclosporine (2)
- Eltrombopag + Rituximab (1)
- Without previous cycles of corticosteroids or further treatment (12)

CONCLUSIONS
1. Eltrombopag was used on-label in most patients and a high percentage started with the recommended dose according to the SmPC.
2. The evolution of the platelet count shows the efficacy of eltrombopag, with a minority of patients having platelet counts below 50.000 platelets/µL and only eleven patients requiring adjuvant treatment.